Women’s Health Still Key to Bayer Despite Early Research Shift
Exit Rumors Inaccurate
The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.
You may also be interested in...
The German company’s two top sellers are marketed by partners in the US, but Bayer will pocket all US sales from its four newest products, at a time when pressures are mounting at home and abroad.
Veozah received approval from the US FDA for a common symptom of menopause, a therapeutic area that has lacked pharmaceutical advancements.
The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.